AKTX
HEALTHCAREAkari Therapeutics Plc
$5.82+0.20 (+3.56%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving AKTX Today?
No stock-specific AI insight has been generated for AKTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.25$56.80
$5.82
Fundamentals
Market Cap$7M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume12K
Avg Volume (10D)—
Shares Outstanding1.1M
AKTX News
20 articles- European Equities Traded in the US as American Depositary Receipts Heading Lower in Thursday TradingYahoo Finance·May 7, 2026
- European Equities Traded in the US as American Depositary Receipts Climb Sharply Higher in Wednesday TradingYahoo Finance·May 6, 2026
- European Equities Traded in the US as American Depositary Receipts Start Week LowerYahoo Finance·May 4, 2026
- European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for WeekYahoo Finance·May 1, 2026
- European Equities Traded in the US as American Depositary Receipts Lower in Wednesday TradingYahoo Finance·Apr 29, 2026
- European Equities Traded in the US as American Depositary Receipts Track Lower in Monday TradingYahoo Finance·Apr 27, 2026
- Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC PayloadYahoo Finance·Apr 27, 2026
- European Equities Traded in US as ADRs Ease in Thursday TradingYahoo Finance·Apr 23, 2026
- European Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday TradingYahoo Finance·Apr 22, 2026
- European Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday TradingYahoo Finance·Apr 21, 2026
- Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant TumorsYahoo Finance·Apr 21, 2026
- Maxim Sees High Risk Profile for Akari Therapeutics, plc (AKTX) Amid Capital NeedsYahoo Finance·Apr 21, 2026
- Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA SplicingYahoo Finance·Apr 20, 2026
- European Equities Traded in the US as American Depositary Receipts Rise in Friday TradingYahoo Finance·Apr 10, 2026
- Akari Therapeutics downgraded to Hold from Buy at MaximYahoo Finance·Apr 10, 2026
- Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDCYahoo Finance·Apr 9, 2026
- European Equities Traded in the US as American Depositary Receipts Surge in Wednesday TradingYahoo Finance·Apr 8, 2026
- European Equities Traded in the US as American Depositary Receipts Decline in Monday TradingYahoo Finance·Apr 6, 2026
- Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA SplicingYahoo Finance·Apr 6, 2026
- European Equities Traded in the US as American Depositary Receipts Decline in Thursday TradingYahoo Finance·Apr 2, 2026
All 20 articles loaded
Price Data
Open$5.55
Previous Close$5.62
Day High$6.15
Day Low$5.36
52 Week High$56.80
52 Week Low$3.25
52-Week Range
$3.25$56.80
$5.82
Fundamentals
Market Cap$7M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume12K
Avg Volume (10D)—
Shares Outstanding1.1M
About Akari Therapeutics Plc
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. The company is headquartered in London, the United Kingdom.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—